Glembatumumab vedotin Completed Phase 2 Trials for Recurrent Osteosarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02487979Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma